Clôture précédente | 75,42 |
Ouverture | 75,51 |
Offre | 74,76 x 1000 |
Vente | 74,80 x 1200 |
Var. jour | 74,58 - 75,75 |
Sur 52 semaines | 61,45 - 89,74 |
Volume | |
Volume moyen | 5 471 366 |
Cap. boursière | 93,202B |
Bêta (mensuel sur 5 ans) | 0,39 |
Rapport P/E (sur 12 mois) | 17,20 |
BPA (sur 12 mois) | 4,35 |
Date de bénéfices | 25 oct. 2023 - 30 oct. 2023 |
Dividende et rendement à terme | 3,00 (3,98 %) |
Date ex-dividende | 14 sept. 2023 |
Objectif sur 1 an | 91,04 |
NORHAMPTON, MA / ACCESSWIRE / November 10, 2022 / Gilead Sciences While Jesse Garcia was growing up in Chicago's inner city, his parents didn't immediately turn to a doctor when someone in the family got sick. "We relied on traditional Latino ...
NORTHAMPTON, MA / ACCESSWIRE / November 2, 2022 / Gilead Sciences Since the beginning of the COVID-19 pandemic, Gilead's first-in-class antiviral was made available to more than 11 million patients globally- over 65% of whom live in low-and lower-middle-income ...
In the spring of 2018, North Carolina native Stephanie Walker went to her first breast cancer conference and had a revelation that she refers to as her "coming-out party." She learned she had metastatic breast cancer three years earlier and although she was a retired hospice nurse, she faced the disease without any guidance from others who shared her experience.